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ABSTRACT
Introduction: Multimorbidity (MM) refers to the
coexistence of two or more chronic conditions within
one person, where no one condition is considered
primary. As populations age and healthcare provision
improves, MM is becoming increasingly common and
poses a challenge to the single morbidity approach to
illness management, usually adopted by healthcare
systems. Indeed, recent research has shown that
66.2% of the people in primary care in Ireland are
living with MM. Healthcare usage and cost is
significantly associated with MM, and additional
chronic conditions lead to exponential increases in
service usage and financial costs, and decreases in
physical and mental well-being. Certain conditions, for
example, chronic pain, are highly correlated with MM.
This study aims to assess the extent, profile, impact
and cost of MM among Irish adults with chronic pain.
Methods and analysis: Using cluster sampling,
participants aged 18 years and over will be recruited
from Irish pain clinics and provided an information
package and questionnaire asking them to participate
in our study at three time points, 1 year apart. The
questionnaire will include our specially developed
checklist to assess the prevalence and impact of MM,
along with validated measures of quality of life, pain,
depression and anxiety, and illness perception.
Economic data will also be collected, including direct
and indirect costs.
Ethics and dissemination: Ethical approval has
been granted by the Research Ethics Committee of the
National University of Ireland, Galway. Dissemination of
results will be via journal articles and conference
presentations.
INTRODUCTION
The guidelines for chronic disease manage-
ment have traditionally taken a single disease
approach,1 which presents a challenge for
patients who have multiple, sometimes dis-
cordant chronic conditions. As such, it has
been argued that a single-morbidity
approach in the context of multiple health
conditions typically leads to inadequate
disease management.1 Thus, there has been
a call for a more ‘holistic’ consideration of
the patient and a disease management
approach that focuses on multimorbidity.1 2
Multimorbidity (MM) refers to the coexist-
ence of two or more chronic conditions
within one person, where no one condition
takes precedence over another.3 Despite the
increasing interest of healthcare practitioners
in the area of MM, Marengoni et al4 note
that there remains “a remarkable gap
between the harmful impact of multimorbid-
ity at the individual and societal level and the
amount of scientiﬁc and clinical research
devoted to this topic” (p.435).
Prevalence of MM
There are a variety of measures deployed to
assess multimorbidity (eg, Agborsangaya
et al, 5 Britt et al1). Typically, however, preva-
lence research uses some form of checklist
(ie, lists of chronic conditions) to assess the
prevalence of MM in a given population.
Most of the prevalence literature and
Strengths and limitations of this study
▪ The research study aims, to account for the
prevalence and cost of multimorbidity in people
living with chronic pain’, are novel and would
provide useful information for both the applied
and research communities.
▪ Given the cohort of participants, the sample type
may arguably be considered not entirely repre-
sentative of all people living with chronic pain.
▪ The multimorbidity checklist has been designed
based on international best practice guidelines
for an Irish population.
▪ The current study design is time consuming as
ethical approval is required for each study site.
Slattery BW, et al. BMJ Open 2017;7:e012131. doi:10.1136/bmjopen-2016-012131 1
Open Access Protocol
epidemiological work in the area of MM has come from
research in Canada and Australia. Prevalence rates for
these countries are 19% and 37.1%, respectively.1 5
However, epidemiological research has found prevalence
estimates of MM ranging from 17% to over 90% inter-
nationally.5 In their Public Health Review, Boyd and
Fortin3 concluded that approximately one out of every
four adults has two or more chronic conditions, and that
half of all older adults globally have three or more
chronic conditions.
From an Irish perspective, relatively little research on
the prevalence of MM has been conducted; however,
available ﬁgures show that between 27%6 and 66.2%7 of
the population have two or more chronic conditions.
While there is some uncertainty regarding the exact
prevalence rates of MM, it is clear that MM is becoming
increasingly more common.5 Contributing factors to the
increase in MM include ageing populations, better
medical treatments, lifestyle factors and the increased
prevalence of certain diseases in particular populations.5 8
Impact of MM: challenges for patients and health
practitioners
The occurrence of MM has signiﬁcant social, psycho-
logical, economic and physical implications for a person,
creating a variety of management and treatment chal-
lenges.3 For instance, different conditions require differ-
ent and sometimes incompatible treatment solutions
and, as a result, multiple coexisting conditions can com-
plicate medical treatment and affect long-term recovery.
Indeed, MM can contribute to a person becoming
increasingly ill compared to another person with any one
of the same index diseases but without MM, and it has
also been linked to higher rates of postoperative compli-
cations.9 Research on the impact of MM shows that it
causes a decline in physical and mental functioning, is
correlated with mental health issues, negatively inﬂuences
quality of life, ability to work and employability and is
associated with increased mortality risk, as well as longer
hospital stays and higher levels of healthcare usage.3 4 9 10
MM and chronic pain
Chronic pain (CP) is deﬁned as “an unpleasant sensory
and emotional experience associated with actual or
potential tissue damage, or described by the patient in
terms of such damage” that persists for a period in
excess of 3 months.11 CP is a major public health
problem that can have debilitating physical, emotional,
psychological and ﬁnancial consequences for those indi-
viduals living with it (see Azevedo et al12; Kroenke et al13;
Raftery et al14). Prevalence estimates for CP vary across
studies and countries;12–16 one recent study found that
35.5% of the Irish population were living with CP.14
CP is highly correlated with MM, and is consistently
identiﬁed as one of the most common conditions in
those identiﬁed as having MM.5 For example, in one
Canadian study examining the prevalence of disease
combinations, 16 common disease pairs were identiﬁed,
with CP appearing in six of the combinations. Further,
from the ﬁve most common disease triads identiﬁed in
the same study, CP was involved in three of these combi-
nations.5 However, though the prevalence of CP is
highly correlated with MM, little is known about the
experience of chronic pain with other complex condi-
tions.17 To address this issue, Butchart et al17 examined
the experience and management of chronic pain for
people with other chronic conditions. The researchers
found that patients with CP were more likely to report
decreased health than those without CP, and those with
CP and comorbid heart failure or diabetes were less
likely to be in employment.
Given the dearth of research examining the experi-
ence of MM where CP is a feature, as well as the high
correlation and prevalence of CP and MM, it is import-
ant that research examines the prevalence and the rela-
tionship between the two more closely. While previous
studies have examined the prevalence of MM in Irish
samples,7 no previous Irish study has examined the
prevalence of MM in a population of people with CP.
Aims of the current research
1. To determine the prevalence, impact and cost of MM
in a cohort of people in Ireland who live with chronic
pain.
2. To identify the nature and proﬁle of MM in which
chronic pain is a central feature.
3. To develop a predictive model of multimorbid dis-
ability in a population of people with chronic pain.
4. To chart the developmental trajectory of MM in a
sample of people with chronic pain.
METHOD
Design
A prospective cohort study with three time points
(1 year apart) assessing the prevalence of MM in a
cohort of people with chronic pain will be employed.
Data collection and sample size
Inclusion criteria
All participants of this study must be over 18 years of age
and experiencing chronic non-cancer pain (according
to the International Association for the Study of Pain
deﬁnition). Individuals with terminal illness, severe
mental illness or cognitive impairment that would
prevent adequate understanding and participation in the
study will be excluded.
Recruitment
Recruitment will be carried out through Irish pain
clinics. Staff in the pain clinics will inform patients of
the study. Participants will be identiﬁed via the patient
records from each of the 16 pain clinics in the Republic
of Ireland; a list of patients who have visited each clinic
over the previous 18 months will be requested. Each
patient will be given an identiﬁer by one of the members
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of the research team (L’OC), and another member of
the research team (SH) will employ Stata V.13.1 (Stata.
College Station, Texas: StataCorp LP 2013) to randomly
select 150 participants from each clinic. These partici-
pants will be given the survey packs containing the study
information sheets, consent forms, multimorbidity check-
list and questionnaires by the research team. The partici-
pants will be given the option to post their completed
packs to the NUI Galway Centre for Pain Research using
a stamped addressed envelope provided. In addition, the
pack will contain a link to our website where the partici-
pants will be able to complete the survey online should
they prefer this method to the postal system.
Sample size
Sample size was calculated using the equation proposed
for prevalence research by Naing et al.18 To calculate the
sample size for a prevalence study, the expected preva-
lence is required. Based on previous research,6 7 14 19
the expected prevalence of MM in a population of
people with CP is approximately between 22% and 54%.
Nicholl20 notes that if there is a doubt about the preva-
lence total in a given population, researchers should err
towards assuming a 50% prevalence rate as it will yield a
larger sample size. Therefore, using Naing et al’s18 equa-
tion and predicting that 50% of our sample may exhibit
MM, CIs set at 0.95 and the degree of precision (d)
=0.05 produced a sample size of 384. Using a predicted
response rate of 40%, based on previous Irish preva-
lence research in the area of chronic pain, the sample
size was calculated as 960. Since we are sampling from
Irish pain clinics, the design effect of using a cluster ran-
domised trial must be taken into account; however, we
were unable to identify a suitable intracluster correlation
coefﬁcient. Therefore, as demonstrated in a similar
study on prevalence,14 a median value of 0.01 was used.
Adjusting for this, with an average of 150 patients per
cluster, gives a design effect of 2.49 and a sample of
2391. A target sample of 2400 will be recruited, 150
patients from each of the 16 Irish pain clinics.
Measures
Sociodemographic and health information
Participants will be asked to supply details regarding
age, gender, relationship status, highest educational
attainment, occupational status (working full-time,
working part-time, retired, unemployed, occupied with
home duties or other) and their occupation, to deter-
mine socioeconomic status, as well as duration of
chronic conditions, site(s) of chronic pain and cause of
chronic pain. Some details about previous and current
medical and alternative treatments will also be collected.
Primary measure
The main focus of this study is to assess the point preva-
lence of MM in a cohort of people with chronic pain in
Ireland. To that end, a speciﬁc disease count measure was
developed.
Background to current MM checklist
As Diederichs, Berger and Bartels10 highlight, there is
no ‘gold standard’ measure of MM. Several measures of
MM exist and have been developed for a variety of
reasons, including different deﬁnitions of MM, different
purposes for measuring MM, different required or avail-
able resources for data collection and the type of data
available.7 21 Moreover, there are no deﬁnitive criteria
for the selection of chronic conditions that qualify for
MM and, therefore, no standardised list of the number
and type of diseases to be included in a MM measure.10
In a review of the literature, de Groot, Beckerman,
Lankhorst and Bauter22 found that there were 13
common measures of MM: 12 of these were disease
indexes and one was a disease count.
Researchers who are interested in tallying the number
of conditions that occur in patients as an outcome, or
those examining the prevalence of MM, primarily use
disease counts (eg, Bayliss et al21). To develop a
disease count measure, researchers typically select
and include the most common conditions found in
the targeted population. For example, Bayliss et al21
reviewed the literature and selected the 25 most
common chronic conditions for a US sample to
include in their measure. They developed a subjective
scale or disease count, where participants marked
which diseases they had and then rated them in terms
of severity (ie, how much each one affected their
daily functioning).
Although different viewpoints exist regarding what
conditions to include and how they should be selected
for an MM disease count measure, guidelines21 23 have
been proposed to address these issues, which are based
on work yielded from systematic reviews in the area.
Guidelines for developing an MM checklist
Fortin et al23 proposed an operational deﬁnition of MM,
whereby two or more diseases should be present in an
individual and meet the diagnostic criteria for two separ-
ate areas of the Cumulative Illness Rating Scale (CIRS).24
The CIRS is a measure that weights the severity of MM.
It is divided into sections based on 14 different organ
systems. These organ systems are as follows: (1) Cardiac,
(2) Vascular, (3) Haematopoietic, (4) Respiratory, (5)
Eyes, Ears, Nose, Throat and Larynx, (6) Upper
gastrointestinal (GI), (7) Lower GI, (8) Hepatic, (9)
Renal, (10) Genitourinary, (11) Musculoskeletal, (12)
Neurological, (13) Endocrine/Metabolic and Breast, and
(14) Psychiatric. For a person to be considered to have a
diagnosis of MM, chronic disease must be present in at
least two different sections or organ systems. However, it
is not necessary for a disease count to list either all condi-
tions or all CIRS body systems. Fortin et al25 recommend a
minimum of seven conditions and argued that any list of
conditions included in a MM prevalence study should
reﬂect the most common conditions in the population to
be studied.
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Process for developing the current MM checklist
In line with Fortin et al’s26 recommendations, the condi-
tions included in the current disease count question-
naire were obtained from two large-scale national
reports on the Irish population more widely25 26 and
four Irish research studies that had investigated the
prevalence of MM and had compiled lists of conditions
to examine.6 19 26 27 To ensure that the list of conditions
met international best practice recommendations,21 23 in
terms of which conditions to include in an MM disease
count list, we then combined our study with one inter-
national study that examined MM in people living with
CP.5 We also examined two of the most recent systematic
reviews, which outline the most common conditions
included in MM studies and contain recommendations
for the type of conditions to be included in MM check-
lists.10 28 Following this, two healthcare practitioners
were consulted and provided feedback on which condi-
tions to include, and one clinician, who is an expert in
chronic pain, reviewed the entire MM checklist. From
this review process, the three additional categories of
conditions included were as follows: renal disorders,
hepatic disorders and headache disorders. Subsequently,
we collapsed the conditions from this developmental
process with respect to the CIRS organ system domains
and removed any duplicate conditions, leaving us a total
of 34 conditions across 10 organ domains (see table 1).
We also added category options (eg, ‘Other cardiac con-
ditions’) to ensure that useful data could be collected
on conditions that did not appear on the list, as well as a
ﬁnal ‘Any other condition not listed’ category.
Structure of MM checklist and operational definition of MM
Based on Fortin et al’s8 suggestion, a condition will be
deemed suitable for inclusion as a MM when it meets
one or both of the following criteria; a formal diagnosis
has been provided by a doctor, and/or a person is
receiving prescribed medication for the particular condi-
tion. To ensure that participants understand what each
condition is, a lay deﬁnition derived from a medical def-
inition for each condition (see US National Library of
Medicine MeSH database29) will be provided (see online
supplementary appendix A). Furthermore, similar to
Bayliss et al,21 who created a subjective survey disease
count measure of MM, the current measure will include
a rating scale (from 1 to 5; 1 being least impactful and 5
being most impactful) measuring the impact that each
condition has on their daily functioning. The inclusion
of this rating scale will enable the research to identify
which chronic conditions have more of an impact on
daily functioning and, indeed, which disease combina-
tions have more of a cumulative impact on daily
functioning.
Secondary measures
A number of secondary measures will be included to
provide an accurate representation of the impact of MM
and CP on participants. The measures outlined below
were chosen to quantify the prevalence and impact of
MM for people living with CP and were based on inclu-
sion in previous chronic pain and MM prevalence
research.14
Health-related quality of life
The Medical Outcomes Short Form-12 (SF-12)30 will be
used to assess health-related quality of life. The SF-12 is a
general measure of health-related quality of life that has
been used and validated with European populations.31 It
gathers information across 8 health domains: general
health, physical functioning, emotional role limitation,
physical role limitation, mental health, bodily pain, vital-
ity and social functioning. According to the norm-based
method recommended by the test author, these items are
scored to produce a mental component summary and
physical component summary of health-related quality of
life.30 Lower scores on either of these scales are indicative
of a lower quality of life. Irish population norms are avail-
able32 and will be used for comparison with the present
sample. The SF-12 has been used as a measure of
health-related quality of life previously within CP research
and MM research.20 33 34
Depression and anxiety
Depression will be measured using the Patient Health
Questionnaire-9 item (PHQ-9). The PHQ-9 is a widely
used and well validated measure of depression13 and it
has been used with people living with chronic condi-
tions.35 It contains 9 items that relate to the Diagnostic
and Statistical Manual Fourth Edition (DSM IV) criteria
for depression. The items are scored on a four-point
Likert scale ranging from 0 ‘not at all’ to 3 ‘nearly every
day’. The higher the score on the PHQ-9, the more
symptom criteria a person meets. A cut-off score of above
10 indicates moderate depression and a score of above 15
indicates a clinical ‘case’ of moderately severe depression.
Anxiety will be measured using the generalised
anxiety disorder 7-item (GAD-7). The GAD-7 is a vali-
dated and standardised measure of anxiety36 and has
been recommended for use in CP studies.37 It is a
7-item questionnaire that presents items relating to how
often over the past couple of weeks a person has felt
bothered by each of the DSM IV symptom criteria for
GAD. Items are scored on a four-point Likert scale
ranging from 0 ‘not at all’ to 3 ‘nearly every day’. A
higher overall score represents greater symptom severity.
Pain severity and disability
Pain-related severity and disability will be measured by
the Chronic Pain Grade Questionnaire,38 commonly
used in pain research. The Chronic Pain Grade
Questionnaire categorises pain severity into one of four
grades based on two dimensions: intensity and disability,
depending on pain experiences in the previous 3–
6 months. It contains seven items which can be com-
pleted by self-report, and includes questions both about
the pain itself and its impact on daily functioning.
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Table 1 Source and summary of conditions included in the Multimorbidity Checklist
CIRS domain Study and included conditions
Included MM
Checklist
conditions
Teljeur et al27 Naughton et al6 Household
Quarterly
Report 2010
CARDI
2011/Savva
et al 2011
unpublished
manuscript
TILDA 2011
Report: Fifty
plus in Ireland
Diederichs
et al10
(systematic
review)
Sinnige
et al28(systematic
review)
Agborsangaya
et al5
Sinnott et al19
Cardiac Heart disease Hypertension/heart
failure, arrhythmias
Heart Attack,
heart failure
Angina,
heart attack
Cardiovascular
disease
(angina, heart
attack, heart
failure)
Chronic
ischaemic
heart
disease,
arrhythmia,
insufficiency,
infarction
Heart disease,
heart failure,
attack, angina
(coronary artery
disease)
Prior heart
attack,
angina, heart
failure, aortic
aneurysm,
other cardiac
disease,
peripheral
vascular
disease,
Angina,
arrhythmia,
heart failure,
heart attack,
other
Vascular Hypertension Hypertension Hypertension Hypertension Hypertension Hypertension Hypertension Hypertension Hypertension
Haematopoietic High
cholesterol,
hyperlipidaemia,
Hypercholesterolaemia High
cholesterol
Lipid metabolism
disorders
High
cholesterol
High cholesterol
Respiratory Chest/lung
disease, asthma
Respiratory conditions Asthma,
COPD
Respiratory
disease (eg,
bronchitis or
emphysema)
COPD COPD, asthma Asthma,
bronchitis
Asthma,
bronchitis,
emphysema,
COPD, other
Eyes, ears,
nose, throat
and larynx
Glaucoma Eye disease
(eg, glaucoma,
age-related
macular
degeneration,
cataracts)
Glaucoma,
other
UPPER GI
(oesophagus,
stomach,
duodenum)
Gastrointestinal
disease
Gastrointestinal
disease, Other
GI conditions
LOWER GI
*Hepatic Liver disease
(eg, hepatitis)
*Renal Kidney disease
(eg, chronic
kidney disease)
Genitourinary Urinary
incontinence
Urinary
incontinence,
other
Continued
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Table 1 Continued
CIRS domain Study and included conditions
Included MM
Checklist
conditions
Musculoskeletal Arthritis Musculoskeletal
conditions, Pagets/
osteoporosis,
Rheumatological
conditions
Osteoporosis Pain, arthritis,
osteoporosis
Arthritis,
osteoarthritis,
osteoporosis,
chronic back or
neck disorder
Arthritis Chronic back
pain,
osteoarthritis,
osteoporosis,
rheumatoid
arthritis
Back pain or
problem, neck
pain or problem,
osteoporosis,
osteoarthritis,
rheumatoid
arthritis, other
*Headache
disorders
Headache
disorder (eg,
migraine, cluster
headaches,
tension
headaches)
Neurological Parkinson’s disease,
dementia
Stroke Stroke Stroke/TIA Stroke Dementia,
cerebrovascular
disease/stroke
Stroke Stroke, TIA,
Dementia, Other
CNS conditions
Endocrine/
metabolic and
breast
Diabetes,
hypothyroidism,
obesity
Diabetes, thyroid
disorders
Diabetes Diabetes Diabetes Diabetes, thyroid
disease, obesity
Diabetes,
obesity
Thyroid
disease,
diabetes
Diabetes (type
1), Diabetes
(type 2),
hypothyroidism,
obesity Other
Psychiatric Depression Psychiatric disorders,
anxiety
Depression,
anxiety
Depression Depression Depression/
anxiety
Anxiety,
depression
Depression,
anxiety, other
Other
conditions:
Cancer Cancer Cancer Cancer Cancer Cancer Any cancer in
the past 5 years
Epilepsy, gout, sleep
disturbance
Sleep apnoea Epilepsy, gout,
chronic sleep
disturbance
This table summarises the process of integrating previous multimorbidity studies and their listed conditions with the body system (CIRS domain) approach to develop the final list of conditions
that appear in our multimorbidity tool (see the rightmost column). *Conditions included, as a result of advice from a healthcare practitioner.
CIRS, Cumulative Illness Rating Scale; MM, Multimorbidity.
COPD, chronic obstructive pulmonary disease; CNS, central nervous system; GI, gatroinstestinal; TIA, transient ischaemic attack.
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Pain intensity and interference
Intensity of pain and the degree of interference in the
participant’s life will be measured by the Brief Pain
Inventory, speciﬁcally the short form of the tool.39 This
includes nine items, to be completed by self-report, and
asks about pain both now and over time. Two scores are
given: pain severity (out of 40) and pain interference
(out of 70). Higher scores indicate greater pain severity
and interference.
Multimorbidity Illness Perceptions Scale
The Multimorbidity Illness Perceptions Scale
(MULTIPleS)40 was developed to measure patient illness
perceptions in the presence of MM. The MULTIPleS is a
22-item questionnaire. Each item has a Likert scale that
runs from 0 to 3, where ‘0’ indicates that a person
‘strongly disagrees’ with an item and ‘3’ indicates that a
person ‘strongly agrees’ with an item. Overall, the 22
items comprise ﬁve subscales: emotional representation,
treatment burden, prioritising conditions, causal links
and activity limitations. The MULTIPleS is a relatively
new scale, so it has not yet been used as a measure in
clinical research. However, Gibbons et al40 found that
the scale provided a good ﬁt to the Rasch model and
demonstrated evidence of reliability and validity for each
of the subscales.
Economic evaluation
The economic evaluation will be based on a number of
questions relating to usage of healthcare services and
ﬁnancial costs to the participant (similar to Raftery,
Ryan & Normand41). More speciﬁcally, we will examine
costs that fall on the health and social care services by
recording hospitalisations (frequency and duration),
outpatient appointments, accident and emergency
appointments, types and amounts of beneﬁts received
per month, community services used (eg, general practi-
tioner and home help), and medication type, dosage
and frequency. These services/products will be trans-
lated into unit cost data for Ireland and provide an esti-
mate of the cost of MM where CP is a feature for the
health service. Furthermore, we will calculate indirect
costs incurred personally by each individual with MM
and their family. These will include expenditure for
treatments and medications not paid for by the state,
and the travel and wait time costs associated with avail-
ing of health services. Opportunity costs will also be cal-
culated by quantifying work absenteeism or reduced
employment due to MM. To generate these data, infor-
mation on wages will be collected; however, should col-
lection of this information not be possible, we will
extrapolate income from age, education and work type.
Risk of bias
To reduce the risk of participant selection bias, one
researcher (LO’C) will give each potential participant a
unique identiﬁer and another member of the research
team (SH) will use STATA V.13.1 to randomly select
participants. Furthermore, responders will be compared
to non-responders to assess and ensure that there is no
response bias between those who actively participate and
those who do not,
Statistical analyses
Graphical (eg, box plots, labelled scatter plots and case
proﬁle plots) and numerical summaries (means,
medians, SDs and IQRs) will be provided for all variables.
A χ2 test will be used to evaluate the relationship between
gender and number of conditions. ORs will be calculated
for risk factors of MM. Factors associated with MM will be
analysed using univariate multiple regression and hier-
archical regression will be employed to examine the rela-
tionships among the number and type of conditions and
the outcome variables (ie, depression, anxiety, quality of
life, illness perceptions and severity of pain, for
example). All analyses will be conducted using SPSS V.22.
Data monitoring and management
This study will collect non-identifying, minimally invasive
information and as such does not require a formal data
monitoring committee. All information collected will be
stored securely at the research site. Paper documents
will be kept in locked cabinets, and electronic data will
be stored on password-protected databases that can only
be accessed by the research team.
Dissemination
Findings of the study will be disseminated in peer-
reviewed publications following the data analysis.
Researchers will also present the results at conferences.
The research programme website will be regularly
updated with news about the study to facilitate dissemin-
ation to the general public.
Twitter Follow Brian Slattery @brian_slatts
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